Pharmacogenetics of colon cancer and potential implications for 5-fluorouracil-based chemotherapy

Current Pharmacogenomics

Volumn 4, Issue 1, 2006, Pages 57-67

  Mauritz, R ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Leucovorin; Methylenetetrahydrofolate reductase (MTHFR); Polymorphisms; Single nucleotide polymorphism; TS enhancer region (TSER)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLOXURIDINE PHOSPHATE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; THYMIDYLATE SYNTHASE; URACIL; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DNA SYNTHESIS INHIBITION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENZYME METABOLISM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PREDICTION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

EID: 33646159995     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016006776055419     Document Type: Review

References (108)

1. Ackland, S. P. and Peters, G. J. (1999) Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Updat. 2, 205-214.
2. Aherne, G. W. and Brown, S. (1999) The role of uracil misincorporation in thymineless death. In Antifolate Drugs in Cancer Therapy; Jackman, A. L.; Ed.; Humana Press Inc.: Totowa, NJ, pp. 409-421.
3. Beck, A.; Etienne, M. C.; Cheradame, S.; Fischel, J. L.; Formento, P.; Renee, N. and Milano, G. (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil, Eur. J. Cancer 30A, 1517-1522.
4. Calascibetta, A.; Cabibi, D.; Martorana, A.; Sanguedolce, G.; Rausa, L.; Feo, S.; Dardanoni, G. and Sanguedolce, R. (2004) Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. Anticancer Res. 24, 3875-3880.
5. Cao, D. and Pizzorno, G. (2004) Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc.) 40, 431-443.
6. Chazal, M.; Cheradame, S.; Formento, J. L.; Francoual, M.; Formento, P.; Etienne, M. C.; Francois, E.; Richelme, H.; Mousseau, M.; Letoublon, C.; Pezet, D.; Cure, H.; Seitz, J. F. and Milano, G. (1997) Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. Clin Cancer Res. 3, 553-557.
7. Chazal, M.; Etienne, M. C.; Renee, N.; Bourgeon, A.; Richelme, H. and Milano, G. (1996) Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res. 2, 507-510.
8. Chen, J.; Hunter, D. J.; Stampfer, M. J.; Kyte, C.; Chan, W.; Wetmur, J. G.; Mosig, R.; Selhub, J. and Ma, J. (2003) Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 12, 958-962.
9. Cloos, J.; Ugrasena, D. G.; Supryadi, E.; De Lange, D.; Vroling, L.; Peters, G. J.; Kaspers, G. J. L. and Veerman, A. J. P. (2005) High frequency of the 3R/3R polymorphism in the thymidylate synthase enhancer region in Indonesian children. 6th International Symposium and Expert Workshops on Leukemia and Lymphoma. p. 132.
10. Cohen, V.; Panet-Raymond, V.; Sabbaghian, N.; Morin, I.; Batist, G. and Rozen, R. (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 9, 1611-1615.
11. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I. and Van Cutsem, E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345.
12. Di Paolo, A.; Danesi, R.; Falcone, A.; Cionini, L.; Vannozzi, F.; Masi, G.; Allegrini, G.; Mini, E.; Bocci, G.; Conte, P. F. and Del Tacca, M. (2001) Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann. Oncol. 12, 1301-1306.
13. Etienne, M. C.; Chatelut, E.; Pivot, X.; Lavit, M.; Pujol, A.; Canal, P. and Milano, G. (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur. J. Cancer 34, 92-97.
14. Etienne, M. C.; Chazal, M.; Laurent-Puig, P.; Magne, N.; Rosty, C.; Formento, J. L.; Francoual, M.; Formento, P.; Renee, N.; Chamorey, E.; Bourgeon, A.; Seitz, J. F.; Delpero, J. R.; Letoublon, C.; Pezet, D. and Milano, G. (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J. Clin. Oncol. 20, 2832-2843.
15. Etienne, M. C.; Formento, J. L.; Chazal, M.; Francoual, M.; Magne, N.; Formento, P.; Bourgeon, A.; Seitz, J. F.; Delpero, J. R.; Letoublon, C.; Pezet, D. and Milano, G. (2004a) Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14, 785-792.
16. Etienne, M. C.; Ilc, K.; Formento, J. L.; Laurent-Puig, P.; Formento, P.; Cheradame, S.; Fischel, J. L. and Milano, G. (2004b) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br. J. Cancer 90, 526-534.
17. Etienne, M. C.; Lagrange, J. L.; Dassonville, O.; Fleming, R.; Thyss, A.; Renee, N.; Schneider, M.; Demard, F. and Milano, G. (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12, 2248-2253.
18. Fleming, R. A.; Milano, G.; Thyss, A.; Etienne, M. C.; Renee, N.; Schneider, M. and Demard, F. (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 52, 2899-2902.
19. Frosst, P.; Blom, H. J.; Milos, R.; Goyette, P.; Sheppard, C. A.; Matthews, R. G.; Boers, G. J.; den Heijer, M.; Kluijtmans, L. A.; and Van den Heuvel, L. P. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10, 111-113.
20. Fujii, R.; Seshimo, A. and Kameoka, S. (2003) Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int. J Clin. Oncol. 8, 72-78.
21. Gil-Delgado, M. A. (2005) Cancer of the Colon and Rectum. In UICC Manual of Clinical Oncology; Pollock, R. E.; Doroshow, J. H.; Khayat, D.; Nakao, A.; O'Sullivan, B.; Eds.; John Wiley & Sons: Chichester, West Sussex, UK.
22. Graziano, F.; Kawakami, K.; Watanabe, G.; Ruzzo, A.; Humar, B.; Santini, D.; Catalano, V.; Ficarelli, R.; Merriman, T.; Panunzi, S.; Testa, E.; Cascinu, S.; Bearzi, I; Tonini, G. and Magnani, M. (2004) Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. Int. J. Cancer 112, 1010-1014.
23. Grem, J. L. (2005) Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Semin. Oncol. 32, 120-127.
24. Grem, J. L.; Danenberg, K. D.; Behan, K.; Parr, A.; Young, L.; Danenberg, P. V.; Nguyen, D.; Drake, J.; Monks, A. and Allegra, C. J. (2001) Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin. Cancer Res. 7, 999-1009.
25. Harris, B. E.; Song, R.; Soong, S. J. and Diasio, R. B. (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50, 197-201.
26. Heggie, G. D.; Sommadossi, J. P.; Cross, D. S.; Huster, W. J. and Diasio, R. B. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47, 2203-2206.
27. Heidelberger, C.; Chaudhuri, N. K.; Danneberg, P.; Mooren, D.; Griesbach, L.; Duschinsky, R. L.; Schnitzer, R. J.; Pleven, E. and Scheiner, J. (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179, 663-666.
28. Holen, K. D. and Saltz, L. B. (2001) New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol. 2, 290-297.
29. Horie, N.; Aiba, H.; Oguro, K.; Hojo, H. and Takeishi, K. (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197.
30. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R. and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluouroracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
31. Iacopetta, B.; Grieu, F.; Joseph, D. and Elsaleh, H. (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85, 827-830.
32. Ichikawa, W.; Uetake, H.; Shirota, Y.; Yamada, H.; Nishi, N.; Nihei, Z.; Sugihara, K. and Hirayama, R. (2003) Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res. 9, 786-791.
33. Ichikawa, W.; Uetake, H.; Shirota, Y.; Yamada, H.; Takahashi, T.; Nihei, Z.; Sugihara, K.; Sasaki, Y. and Hirayama, R. (2003) Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br. J. Cancer 89, 1486-1492.
34. Iqbal, S. and Lenz, H. J. (2004) Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother. Pharmacol. 54(Suppl. 1), S32-S39.
35. Ishida, Y.; Kawakami, K.; Tanaka, Y.; Kanehira, E.; Omura, K. and Watanabe, G. (2002) Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res. 22, 2805-2809.
36. Jakobsen, A.; Nielsen, J. N.; Gyldenkerne, N. and Lindeberg, J. (2005) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol. 23, 1365-1369.
37. Jiang, H.; Lu, J.; Jiang, J. and Hu, P. (2004) Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J. Clin. Pharmacol. 44, 1260-1272.
38. Johnston, P. G.; Drake, J. C.; Trepel, J. and Allegra, C. J. (1992) Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and - resistant human cancer cell lines. Cancer Res. 52, 4306-4312.
39. Johnston, P. G.; Fisher, E. R.; Rockette, H. E.; Fisher, B.; Wolmark, N.; Drake, J. C.; Chabner, B. A. and Allegra, C. J. (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 12, 2640-2647.
40. Kaneda, S.; Nalbantoglu, J.; Takeishi, K.; Shimizu, K.; Gotoh, O.; Seno, T. and Ayusawa, D. (1990) Structural and functional analysis of the human thymidylate synthase gene. J. Biol. Chem. 265, 20277-20284.
41. Kaneda, S.; Takeishi, K.; Ayusawa, D.; Shimizu, K.; Seno, T. and Altman, S. (1987) Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res. 15, 1259-1270.
42. Kawakami, K.; Salonga, D.; Park, J. M.; Danenberg, K. D.; Uetake, H.; Brabender, J.; Omura, K.; Watanabe, G. and Danenberg, P. V. (2001) Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7, 4096-4101.
43. Kawakami, K. and Watanabe, G. (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63, 6004-6007.
44. Kornmann, M.; Schwabe, W.; Sander, S.; Kron, M.; Strater, J.; Polat, S.; Kettner, E.; Weiser, H. F.; Baumann, W.; Schramm, H.; Hausler, P.; Ott, K.; Behnke, D.; Staib, L.; Beger, H. G. and Link, K. H. (2003) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin. Cancer Res. 9, 4116-4124.
45. Kunz, B. A. (1988) Mutagenesis and deoxyribonucleotide pool imbalance. Mutat. Res. 200, 133-147.
46. Le Marchand, L.; Wilkens, L. R.; Kolonel, L. N. and Henderson, B. E. (2005) The MTHFR C677T Polymorphism and Colorectal Cancer: The Multiethnic Cohort Study. Cancer Epidemiol. Biomarkers Prev. 14, 1198-1203.
47. Lecomte, T.; Ferraz, J. M.; Zinzindohoue, F.; Loriot, M. A.; Tregouet, D. A.; Landi, B.; Berger, A.; Cugnenc, P. H.; Jian, R.; Beaune, P. and Laurent-Puig, P. (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 10, 5880-5888.
48. Leichman, C. G.; Lenz, H. J.; Leichman, L.; Danenberg, K.; Baranda, J.; Groshen, S.; Boswell, W.; Metzger, R.; Tan, M. and Danenberg, P. V. (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15, 3223-3229.
49. Lenz, H. J.; Leichman, C. G.; Danenberg, K. D.; Danenberg, P. V.; Groshen, S.; Cohen, H.; Laine, L.; Crookes, P.; Silberman, H.; Baranda, J.; Garcia, Y.; Li, J. and Leichman, L. (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14, 176-182.
50. Longley, D. B.; Harkin, D. P. and Johnston, P. G. (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338.
51. Mandola, M. V.; Stoehlmacher, J.; Muller-Weeks, S.; Cesarone, G.; Yu, M. C.; Lenz, H. J. and Ladner, R. D. (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63, 2898-2904.
52. Mandola, M. V.; Stoehlmacher, J.; Zhang, W.; Groshen, S.; Yu, M. C.; Iqbal, S.; Lenz, H. J. and Ladner, R. D. (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14, 319-327.
53. Marcuello, E.; Altes, A.; del Rio, E.; Cesar, A.; Menoyo, A. and Baiget, M. (2004) Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int. J. Cancer 112, 733-737.
54. Maring, J. G.; Van Kuilenburg, A. B.; Haasjes, J.; Piersma, H.; Groen, H. J.; Uges, D. R.; Van Gennip, A. H. and De Vries, E. G. (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer 86, 1028-1033.
55. Marsh, S.; Ameyaw, M. M.; Githang'a, J.; Indalo, A.; Ofori-Adjei, D. and McLeod, H. L. (2000) Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. 16, 528.
56. Marsh, S.; Collie-Duguid, E. S.; Li, T.; Liu, X. and McLeod, H. L. (1999) Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58, 310-312.
57. Marsh, S.; McKay, J. A.; Cassidy, J. and McLeod, H. L. (2001) Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19, 383-386.
58. Mattison, L. K.; Ezzeldin, H.; Carpenter, M.; Modak, A.; Johnson, M. R. and Diasio, R. B. (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res. 10, 2652-2658.
59. Mauritz, R.; Beumer, I. J.; Marsh, S.; McLeod, H. L.; Smid, K.; Van Groeningen, C. J.; Pinedo, H. M. and Peters, G. J. (2004) Polymorphisms of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides, Nucleotides and Nucleic Acids 23, 1381-1384.
60. Mauritz, R.; Schwabe, W.; Haeusler, P.; Noordhuis, P.; Smid, K.; McLeod, H. L.; Behnke, D.; Van Groeningen, C. J. and Peters, G. J. (2004) Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR. Nucleosides Nucleotides Nucleic Acids 23, 1471-1474.
61. Maxwell, P. J.; Longley, D. B.; Latif, T.; Boyer, J.; Allen, W.; Lynch, M.; McDermott, U.; Harkin, D. P.; Allegra, C. J. and Johnston, P. G. (2003) Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 63, 4602-4606.
62. McLeod, H. L.; Sargent D.; Marsh, S.; Fuchs, C. S.; Ramanathan, R. K.; Williamson, S. K.; Findlay, B. P.; Thibodeau, S. N.; Petersen, G. M. and Goldberg, R. M. (2003) Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5-FU)/CPT- 11, 5-FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, 52.
63. Merkelbach-Bruse, S.; Hans, V.; Mathiak, M.; Sanguedolce, R.; Alessandro, R.; Ruschoff, J.; Buttner, R.; Houshdaran, F. and Gullotti, L. (2004) Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. Oncol. Rep. 11, 839-843.
64. Metzger, R.; Danenberg, K.; Leichman, C. G.; Salonga, D.; Schwartz, E. L.; Wadler, S.; Lenz, H. J.; Groshen, S. Leichman, L. and Danenberg, P. V. (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. 4, 2371-2376.
65. Moertel, C. G. (1994) Chemotherapy for colorectal cancer. N. Engl. J. Med. 330, 1136-1142.
66. Morganti, M.; Ciantelli, M.; Giglioni, B.; Putignano, A. L.; Nobili, S.; Papi, L.; Landini, I.; Napoli, C.; Valanzano, R.; Cianchi, F.; Boddi, V.; Tonelli, F.; Cortesini, C.; Mazzei, T.; Genuardi, M.; Mini, E. (2005) Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancer. Eur. J. Cancer 41, 2176-2183.
67. Naguib, F. N.; el Kouni, M. H. and Cha, S. (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45, 5405-5412.
68. Nishina, T.; Hyodo, I.; Miyaike, J.; Inaba, T.; Suzuki, S. and Shiratori, Y. (2004) The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridine. Eur. J. Cancer 40, 1566-1571.
69. O'Connell, J. B.; Maggard, M. A. and Ko, C. Y. (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 96, 1420-1425.
70. Park, D. J.; Stoehlmacher, J.; Zhang, W.; Tsao-Wei, D.; Groshen, S. and Lenz, H. J. (2002) Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 17, 46-49.
71. Peters, G. J. (2002) Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on Its Cytotoxic Effects; Preclinical and Clinical Modulation. In Fluoropyrimidines in Cancer Therapy; Rustum, Y. M.; Ed.; Humana Press Inc.: Totowa, NJ, pp. 1-27.
72. Peters, G. J. and Ackland, S. P. (1995a) New antimetabolites in preclinical and clinical development. Exp. Opin. Invest. New Drugs 5, 637-679.
73. Peters, G. J.; Backus, H. H.; Freemantle, S.; Van Triest, B.; Codacci-Pisanelli, G.; Van der Wilt, C. L.; Smid, K.; Lunec, J.; Calvert, A. H.; Marsh, S.; McLeod, H. L.; Bloemena, E.; Meijer, S.; Jansen, G.; Van Groeningen, C. J. and Pinedo, H. M. (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim. Biophys. Acta 1587, 194-205.
74. Peters, G. J.; Smorenburg, C. H. and Van Groeningen, C. J. (2004) Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J. Chemother. 16(Suppl 4), 25-30.
75. Peters, G. J.; Van der Wilt, C. L.; Van Groeningen, C. J.; Smid, K.; Meijer, S. and Pinedo, H. M. (1994) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol. 12, 2035-2042.
76. Peters, G. J.; Van der Wilt, C. L.; Van Triest, B.; Codacci-Pisanelli, G.; Johnston, P. G.; Van Groeningen, C. J. and Pinedo, H. M. (1995b) Thymidylate synthase and drug resistance. Eur. J. Cancer 31A, 1299-1305.
77. Popat, S.; Matakidou, A. and Houlston, R. S. (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 22, 529-536.
78. Pullarkat, S. T.; Stoehlmacher, J.; Ghaderi, V.; Xiong, Y. P.; Ingles, S. A.; Sherrod, A.; Warren, R.; Tsao-Wei, D.; Groshen, S. and Lenz, H. J. (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70.
79. Raida, M.; Schwabe, W.; Hausler, P.; Van Kuilenburg, A. B.; Van Gennip, A. H.; Behnke, D. and Hoffken, K. (2001) Prevalence of a common point mutation in the dibydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7, 2832-2839.
80. Rustum, Y. M.; Harstrick, A.; Cao, S.; Vanhoefer, U.; Yin, M. B.; Wilke, H. and Seeber, S. (1997) Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15, 389-400.
81. Salonga, D.; Danenberg, K. D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D. D.; Lenz, H. J.; Leichman, C. G.; Leichman, L.; Diasio, R. B. and Danenberg, P. V. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327.
82. Shi, Q.; Zhang, Z.; Neumann, A. S.; Li, G.; Spitz, M. R. and Wei, Q. (2005) Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis 26, 649-656.
83. Shintani, Y.; Ohta, M.; Hirabayashi, H.; Tanaka, H.; Iuchi, K.; Nakagawa, K.; Maeda, H.; Kido, T.; Miyoshi, S. and Matsuda, H. (2003) New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int. J. Cancer 104, 790-795.
84. Skibola, C. F.; Smith, M. T.; Hubbard, A.; Shane, B.; Roberts, A. C.; Law, G. R.; Rollinson, S.; Roman, E.; Cartwright, R. A. and Morgan, G. J. (2002) Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Biood 99, 3786-3791.
85. Skibola, C. F.; Smith, M. T.; Kane, E.; Roman, E.; Rollinson, S.; Cartwright, R. A. and Morgan, G. (1999) Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl. Acad. Sci. USA 96, 12810-12815.
86. Smorenburg, C. H.; Peters, G. J.; Van Groeningen, C. J.; Noordhuis, P.; Smid, K.; Van Riel, A. M.; Dercksen, W.; Pinedo, H. M.; Giaccone, G. (2006) Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann. Oncol. 17, 35-42. [Epub ahead of print, October 26, 2005].
87. Sohn, K. J.; Croxford, R.; Yates, Z.; Lucock, M. and Kim, Y. I. (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J. Natl. Cancer Inst. 96, 134-144.
88. Swain, S. M.; Lippman, M. E.; Egan, E. F.; Drake, J. C.; Steinberg, S. M. and Allegra, C. J. (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7, 890-899.
89. Takeishi, K.; Kaneda, S.; Ayusawa, D.; Shimizu, K.; Gotoh, O. and Seno, T. (1985) Nucleotide sequence of a functional cDNA for human thymidylate synthase. Nucleic Acids Res. 13, 2035-2043.
90. Tan, B. R. and McLeod, H. L. (2005) Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin. Oncol. 32, 113-119.
91. Thirion, P.; Michiels, S.; Pignion, J. P.; Buyse, M.; Braud, A. C.; Carlson, R. W.; O'Connell, M.; Sargent, P. and Piedbois, P. (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 22, 3766-3775.
92. Tsuji, T.; Hidaka, S.; Sawai, T.; Nakagoe, T.; Yano, H.; Haseba, M.; Komatsu, H.; Shindou, H.; Fukuoka, H.; Yoshinaga, M.; Shibasaki, S.; Nanashima, A.; Yamaguchi, H.; Yasutake, T. and Tagawa, Y. (2003) Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Cancer Res. 9, 3700-3704.
93. Uchida, K.; Hayashi, K.; Kuramochi, H. and Takasaki, K. (2001) Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int. J. Oncol. 19, 341-346.
94. Ulrich, C. M.; Bigler, J.; Bostick, R.; Fosdick, L. and Potter, J. D. (2002) Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res. 62, 3361-3364.
95. Ulrich, C. M.; Bigler, J.; Velicer, C. M.; Greene, E. A.; Farin, F. M. and Potter, J. D. (2000) Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 9, 1381-1385.
96. Van der Wilt, C. L.; Van Groeningen, C. J.; Pinedo, H. M.; Smid, K.; Hoekman, K.; Meijer, S. and Peters, G. J. (1997) 5-fluorouracil/ leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and man. J. Cancer Res. Clin. Oncol. 123, 595-601.
97. Van Kuilenburg, A. B. (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40, 939-950.
98. Van Kuilenburg, A. B.; Blom, M. J.; Van Lenthe, H.; Mul, E. and Van Gennip, A. H. (1997) The activity of dihydropyrimidine dehydrogenase in human blood cells. J. Inherit. Metab. Dis. 20, 331-334.
99. Van Kuilenburg, A. B.; Haasjes, J.; Richel, D. J.; Zoetekouw, L.; Van Lenthe, H.; De Abreu, R. A.; Maring, J. G.; Vreken, P. and Van Gennip, A. H. (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6, 4705-4712.
100. Van Kuilenburg, A. B.; Meinsma, R.; Zoetekouw, L. and Van Gennip, A. H. (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int. J. Cancer 101, 253-258.
101. Van Kuilenburg, A. B.; Van Lenthe, H.; Blom, M. J.; Mul, E. P. and Van Gennip, A. H. (1998) The activity of dihydropyrimidine dehydrogenase in human blood cells. Adv. Exp. Med. Biol. 431, 823-826.
102. Van Triest, B. (2000) Prognostic value of thymidylate synthase in patients with colorectal cancer; implications for enzyme-directed therapy (Thesis). Vrije Universiteit, Amsterdam.
103. Van Triest, B. and Peters, G. J. (1999) Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 57, 179-194.
104. Veer't, L. J.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M.; Peterse, H. L.; van der, K. K.; Marton, M. J.; Witteveen, A. T.; Schreiber, G. J.; Kerkhoven, R. M.; Roberts, C.; Linsley, P. S.; Bernards, R. and Friend, S. H. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
105. Villafranca, E.; Okruzhnov, Y.; Dominguez, M. A.; Garcia-Foncillas, J.; Azinovic, I.; Martinez, E.; Illarramendi, J. J.; Arias, F.; Martinez, M. R.; Salgado, E.; Angeletti, S. and Brugarolas, A. (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19, 1779-1786.
106. Wang, Y.; Klijn, J. G.; Zhang, Y.; Sieuwerts, A. M.; Look, M. P.; Yang, F.; Talantov, D.; Timmermans, M.; Meijer-van Gelder, M. E.; Yu, J.; Jatkoe, T.; Berns, E. M.; Atkins, D. and Foekens, J. A. (2005) Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 365, 671-679.
107. Weiss, M. M.; Kuipers, E. J.; Postma, C.; Snijders, A. M.; Siccama, I.; Pinkel, D.; Westerga, J.; Meuwissen, S. G.; Albertson, D. G. and Meijer, G. A. (2003) Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene 22, 1872-1879.
108. Zhang, J.; Cui, Y.; Kuang, G.; Li, Y.; Wang, N.; Wang, R.; Guo, W.; Wen, D.; Wei, L.; Yu, F. and Wang, S. (2004) Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Carcinogenesis 25, 2479-2485.